location： Home > Products > Signaling Pathways > Cytoskeletal Signaling > PAK

PF-3758309

Price：

Market Price：

This product is for research use only, not for human use. We do not sell to patients.

Number： - + Pieces（InventoryPieces）

InvivoChem Cat #: V1594

CAS #: 898044-15-0Purity ≥98%

Description: PF-03758309, a pyrrolopyrazole analog, is a novel, potent, orally bioavailable, and ATP-competitive small molecule inhibitor of PAK4 (p21-activated kinase 4) with IC50 of 1.3 NM. As an inhibitor of PAK4,PF-3758309 has potential antineoplastic activity. PF-03758309 binds to PAK4 and inhibits PAK4 activity and cancer cell growth. PAK4, a serine/threonine kinase belonging to the p21-activated kinase (PAK) family, is often upregulated in a variety of cancer cell types and plays an important role in cancer cell motility, proliferation, and survival.

References: Proc Natl Acad Sci U S A. 2010 May 18;107(20):9446-51.

Customer Validation

Official Supplier of

Related Products

Publications Citing InvivoChem Products

Physicochemical and Storage Information
Protocol
Quality Control Documentation
Related Biological Data
Customer Review

Molecular Weight (MW)	490.62
Formula	C25H30N8OS
CAS No.	898044-15-0
Storage	-20℃ for 3 years in powder form
Storage	-80℃ for 2 years in solvent
Solubility (In vitro)	DMSO: 98 mg/mL (199.7 mM)
	Water: <1 mg/mL
	Ethanol: 98 mg/mL (199.7 mM)
Other info	Chemical Name: (S)-N-(2-(dimethylamino)-1-phenylethyl)-6,6-dimethyl-3-((2-methylthieno[3,2-d]pyrimidin-4-yl)amino)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide. InChi Key: AYCPARAPKDAOEN-LJQANCHMSA-N InChi Code: InChI=1S/C25H30N8OS/c1-15-26-18-11-12-35-20(18)23(27-15)29-22-17-13-33(25(2,3)21(17)30-31-22)24(34)28-19(14-32(4)5)16-9-7-6-8-10-16/h6-12,19H,13-14H2,1-5H3,(H,28,34)(H2,26,27,29,30,31)/t19-/m1/s1 SMILES Code: O=C(N(C1)C(C)(C)C2=C1C(NC3=C4C(C=CS4)=NC(C)=N3)=NN2)N[C@@H](C5=CC=CC=C5)CN(C)C
Synonyms	PF-03758309; PF03758309; PF 03758309; PF-3758309; PF-3758309; PF3758309; PF 3758309.

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
- Mass
- Concentration
- Volume
- Molecular Weight *
- =
- ×
- ×
The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂
- Concentration _(start)
- ×
- Volume _(start)
- =
- Concentration _(final)
- ×
- Volume _(final)
- ×
- =
- ×
- C1
- V1
- C2
- V2

In Vitro	In vitro activity: PF-3758309 is a potent (Kd = 2.7 nM), ATP-competitive inhibitor of PAK4 with Ki of 18.7 nM. In cells, PF-3758309 inhibits phosphorylation of the PAK4 substrate GEF-H1 (IC50 = 1.3 nM) and anchorage-independent growth of a panel of tumor cell lines (IC50 = 4.7 nM). PF-3758309 also inhibits endogenous pGEF-H1 accumulation in HCT116 cells. PF-3758309 potently inhibits cellular proliferation (IC50 = 20 nM) and anchorage-independent growth (IC50 = 27 nM) of A549 cells. Kinase Assay: TR-293-KDG cells are constructed from HEK293 cells stably transfected with tetracycline-inducible PAK4-kinase domain (amino acids 291-591) and constitutively expressed HA-tagged GEFH1ΔDH (amino acids 210-921). TR-293-KDG cells are incubated for 3 h with PF-3758309, captured on an anti-HA antibody-coated plate, detected with an anti-phospho-S810-GEF-H1 antibody, and quantified with a horseradish peroxidase-goat anti-rabbit antibody conjugate. Cell Assay: A panel of cancer cell lines is used to test the potency of PF-3758309. On day 1, cells are plated on 384-well plates. Onday2, compounds are added to the cell culture. The cells are incubated with the compound for 3 days. On day 5, all media are aspirated from the wells. Dose-dependent effects of PF-3758309 on cell proliferation are quantified via the CellTiter-Glo Luminescent Cell Viability Assay(a,b,c), which is a homogeneous method of determining the number of viable cells in culture based on quantitation of the ATP present, an indicator of metabolically active cells. Proliferation data displayed for HEK293T, HCT116, and SKOV3 cells are measured using the Cyquant NF assay as specified by the manufacturer. Briefly, 24 h after seeding on 384-well plates, cells are treated with vehicle or PF-3758309, Dasatinib, or the positive control, Bleomycin (60 mU/ mL).72 hours after drug treatment, cell proliferation is measured. Results for each drug are normalized to vehicle control and expressed as a percentage of maximum assay inhibition relative to Bleomycin. Error bars represent the SD from at least three experiments.
In Vivo	PF-3758309 blocks the growth of multiple human tumor xenografts, with a plasma EC50 value of 0.4 nM in the most sensitive model. PF-3758309 is antiproliferative and induces apoptosis in a HCT116 tumor model.
Animal model	Xenograft tumors in nude mice
Formulation & Dosage	Dissolved in 0.5% methylcellulose; 7.5-30 mg/kg BID; p.o. administration
References	Proc Natl Acad Sci U S A. 2010 May 18;107(20):9446-51.

These protocols are for reference only. InvivoChem does not independently validate these methods.

Purity ≥98%
COA
MSDS

PF-3758309 has a unique profile of cellular activity. Proc Natl Acad Sci U S A. 2010 May 18;107(20):9446-51.	PF-3758309 is antiproliferative and induces apoptosis in a HCT116 tumor model. Proc Natl Acad Sci U S A. 2010 May 18;107(20):9446-51. Structural characterization of PF-3758309 binding to the PAK4 catalytic domain. Proc Natl Acad Sci U S A. 2010 May 18;107(20):9446-51.	Tumor growth inhibition of human xenograft tumor models. PF-3758309 is antiproliferative and induces apoptosis in a HCT116 tumor model. Proc Natl Acad Sci U S A. 2010 May 18;107(20):9446-51.